drugset / Trial / NCT03846583
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Non-randomizedSequentialOpen-labelTreatment
Summary
This research study is studying a combination of drugs as a possible treatment for HER2-Postive Metastatic Breast Cancer. The interventions involved in this study are: * Tucatinib * Abemaciclib (VerzenioTM) * Trastuzumab (Herceptin®) * Endocrine Therapy: Exemestane (Aromasin®), Letrozole (Femara®), or Anastrozole (Arimidex®)
Timeline
- Start
- 2020-06-28
- Primary completion
- 2020-09-22
- Completion
- 2020-09-22
Outcome
Outcome not reported
Stopped (Enrollment): “Study halted prematurely, prior to enrollment of first participant.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Tucatinib | Small molecule | — | Oral |
| Background | Anastrozole | Other / unclassified | — | Oral |
| Background | Exemestane | Small molecule | — | Oral |
| Background | Letrozole | Other / unclassified | — | Oral |